Johnson & Johnson JNJ NYSE

Johnson & Johnson (JNJ) reported total assets of $199.21B and total liabilities of $117.67B for fiscal year 2025, resulting in total equity of $81.54B.

The company held $20.1B in cash and short-term investments. Total debt stood at $47.93B, with net debt of $28.22B. The Debt-to-Equity (D/E) ratio was 0.59 (moderate).

Current ratio is 1.03, suggesting adequate short-term liquidity. Interest coverage is 26.4x (strong).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (100/100) — Total assets $199.21B and equity $81.54B support the company's competitive scale
• VALUE (38/100) — Debt-to-Equity 0.59 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 73/100 with 4/7 criteria passed.

LLY

Eli Lilly and Company

$922.50

-0.76%

ABBV

AbbVie Inc.

$210.32

+1.86%

AZN

AstraZeneca PLC

$204.38

+1.06%

MRK

Merck & Co., Inc.

$119.96

-0.16%

NVS

Novartis AG

$153.38

-0.71%

UNH

UnitedHealth Group Incorporated

$314.19

+0.38%

AMGN

Amgen Inc.

$350.95

+0.32%

NVO

Novo Nordisk A/S

$39.32

+3.53%